截至2026年2月26日收盘，微泰医疗-B(02235.HK)报收于7.45港元，上涨0.27%，成交量2.68万股，成交 额19.97万港元。投行对该股的评级以强推为主，近90天内共有1家投行给出强推评级，近90天的目标均 价为13.7港元。华创证券最新一份研报给予微泰医疗-B强推评级，目标价13.7港元。 微泰医疗-B(02235.HK)发布公告，预计集团截至2025年12月31日年度的收入将不低于人民币6.50亿元， 同比增长约88.1%。预计集团2025年度实现归属于母公司所有者的净利润将不低于人民币3800万元，对 比2024年度的人民币-6310万元，增长人民币1.011亿元。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 机构评级详情见下表： 微泰医疗-B港股市值12.31亿港元，在医疗器械Ⅱ行业中排名第18。主要指标见下表： ...

微创心通-B(02160.HK)发布公告，近日，国家药品监督管理局"NMPA"医疗器械技术审评中心发布《创 新医疗器械特别审查申请审查结果公示(2026年第3 号)》，拟同意集团旗下新一代植入式心律转复除颤 器(ICD)TILEN/EYLEN (泰然╱怡然)进入创新医疗器械特别审查程序(NMPA绿色通道)。 据此 ， TILEN/EYLEN(泰然╱怡然)有望成为国内首款获批的具备自主知识产权的磁共振条件安全ICD。 截至2026年2月13日收盘，微创心通-B(02160.HK)报收于0.79港元，上涨2.6%，成交量847.2万股，成交 额661.43万港元。投行对该股的评级以买入为主，近90天内共有1家投行给出买入评级。中信建投最新 一份研报给予微创心通-B买入评级。 微创心通-B港股市值49.02亿港元，在医疗器械Ⅱ行业中排名第9。主要指标见下表： | 指标 | 微创心通-B | 医疗器械I 行业平均 | 行业排名 | | --- | --- | --- | --- | | ROE | 0.24% | -4.82% | 17 28 | | 港股流通市值 | 49.02 Z | 52.01亿 | 9 28 ...

Group 1 - The core point of the article is that Peijia Medical-B (09996.HK) has submitted a CE mark registration application for its GeminiOne transcatheter edge-to-edge repair (TEER) system for treating mitral valve regurgitation, indicating steady progress in its global strategy [1] - The company has a market capitalization of HKD 4.288 billion and ranks 12th in the medical device II industry [1] - The stock has received a buy rating from one investment bank in the last 90 days, with CITIC Securities providing the latest buy rating for Peijia Medical-B [1] Group 2 - HighLife SAS is identified as the European partner for Peijia Medical-B in the CE mark registration process [1] - The article includes a summary of key indicators for Peijia Medical-B, although specific metrics are not detailed in the provided text [1]

奥星生命科技(06118.HK)发布公告，根据就本集团截至2025年12月31日止年度的未经审核综合管理账目 及就董事会目前可取得资料所作的初步评估，预期将取得截至2025年12月31日止年度本公司拥有人应占 溢利不少于人民币3000万元，而截至2024年12月31日止年度本公司拥有人应占溢利约为人民币1600万 元。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2026年2月6日收盘，奥星生命科技(06118.HK)报收于0.8港元，下跌4.76%，成交量12.2万股，成交 额9.87万港元。投行对该股关注度不高，90天内无投行对其给出评级。 奥星生命科技港股市值4.31亿港元，在医疗器械Ⅱ行业中排名第25。主要指标见下表： ...

Core Viewpoint - The company, Qiming Medical-B (02500.HK), has filed a patent infringement lawsuit against Edwards Lifesciences Corp. and Edwards Lifesciences LLC through its wholly-owned subsidiary, Cardiovalve Ltd., in the U.S. District Court for Delaware [1] Company Summary - Qiming Medical-B has a market capitalization of HKD 1.491 billion and ranks 17th in the medical device II industry [1] - The company has a Return on Equity (ROE) of -26.56%, significantly lower than the industry average of -4.82% [1] - The company's operating revenue stands at HKD 427 million, compared to the industry average of HKD 1.201 billion, placing it 18th in the industry [1] - The net profit margin is -72.02%, while the industry average is -19.02%, ranking 26th [1] - The gross profit margin is 73.74%, which is higher than the industry average of 53.75%, ranking 2nd [1] - The company's debt ratio is 33.77%, compared to the industry average of 29.81%, ranking 21st [1] Industry Summary - There has been low attention from investment banks towards Qiming Medical-B, with no ratings given in the past 90 days [1]

Core Viewpoint - MicroTech Medical-B (02235.HK) announced the grant of a total of 3.3 million shares to 51 qualified individuals under its share incentive plan adopted on December 24, 2025, with the shares pending acceptance by the grantees [1] Company Summary - As of December 30, 2025, MicroTech Medical-B closed at HKD 7.93, up 2.72%, with a trading volume of 57,000 shares and a turnover of HKD 444,000 [1] - The stock has a market capitalization of HKD 1.282 billion, ranking 18th in the medical device II industry [1] Investment Ratings - The majority of investment banks have a buy rating for MicroTech Medical-B, with one bank issuing a buy rating in the last 90 days [1] - CITIC Securities recently provided a buy rating for MicroTech Medical-B [1] Key Financial Metrics - Return on Equity (ROE): -1.36%, compared to the industry average of -4.85%, ranking 19th [1] - Market capitalization: HKD 1.282 billion, with the industry average at HKD 5.097 billion, ranking 18th [1] - Revenue: HKD 441 million, with the industry average at HKD 1.2 billion, ranking 17th [1] - Net Profit Margin: -0.93%, compared to the industry average of -19.0%, ranking 17th [1] - Gross Margin: 51.66%, with the industry average at 54.03%, ranking 17th [1] - Debt Ratio: 10.8%, compared to the industry average of 29.53%, ranking 5th [1]

Core Viewpoint - Furuya Medical Technology (01696.HK) announced a leadership change, with current Executive Director and Chairman Liu Yi transitioning to a non-executive director role effective January 1, 2026, while retaining membership in the nomination committee [1] Company Summary - As of December 8, 2025, Furuya Medical Technology's stock closed at HKD 4.16, down 0.95%, with a trading volume of 570,800 shares and a turnover of HKD 2.39 million [1] - The company has a market capitalization of HKD 1.967 billion, ranking 14th in the medical device II industry [1] Investment Ratings - The majority of investment banks have a "Buy" rating for the stock, with one bank issuing a "Buy" rating in the last 90 days [1] - Huaxi Securities provided a recent report recommending a "Buy" rating for Furuya Medical Technology [1] Key Financial Metrics - Return on Equity (ROE): 4.44%, compared to the industry average of -4.03%, ranking 13th [1] - Market capitalization in Hong Kong: HKD 1.967 billion, with the industry average at HKD 5.116 billion, ranking 14th [1] - Revenue: HKD 346 million, while the industry average is HKD 1.195 billion, ranking 21st [1] - Net Profit Margin: 5.43%, compared to the industry average of -16.5%, ranking 16th [1] - Gross Profit Margin: 60.04%, above the industry average of 54.89%, ranking 13th [1] - Debt Ratio: 22.99%, lower than the industry average of 29.03%, ranking 13th [1]

Core Viewpoint - Peijia Medical-B (09996.HK) announced that its CEO and Chairman, Dr. Zhang Yi, will start purchasing company shares in the open market from December 1, 2025, with a total expenditure not exceeding HKD 15 million [1] Group 1: Company Actions - The CEO will begin share purchases on December 1, 2025 [1] - The total cost of the share buyback is expected to be no more than HKD 15 million [1] Group 2: Stock Performance - As of December 5, 2025, Peijia Medical-B closed at HKD 5.54, an increase of 0.73% [1] - The trading volume was 1.0137 million shares, with a total transaction value of HKD 5.6187 million [1] Group 3: Analyst Ratings - The stock has a predominant buy rating from investment banks, with one bank issuing a buy rating in the last 90 days [1] - CITIC Securities recently provided a buy rating for Peijia Medical-B [1] Group 4: Market Position and Financial Metrics - Peijia Medical-B has a market capitalization of HKD 3.693 billion, ranking 11th in the medical device II industry [1] - Key financial metrics include: - ROE: -10.75% (industry average: -4.03%, ranking: 24th) [1] - Market capitalization: HKD 3.693 billion (industry average: HKD 5.177 billion, ranking: 11th) [1] - Revenue: HKD 668 million (industry average: HKD 1.195 billion, ranking: 15th) [1] - Net profit margin: -20.14% (industry average: -16.5%, ranking: 25th) [1] - Gross margin: 70.07% (industry average: 54.89%, ranking: 62nd) [1] - Debt ratio: 23.63% (industry average: 29.03%, ranking: 15th) [1]

Group 1 - The company, 加和国际控股 (08513.HK), announced a proposal to consolidate every 10 existing shares into 1 consolidated share [1] - Following the share consolidation, the trading unit on the Hong Kong Stock Exchange will change from 20,000 existing shares to 5,000 consolidated shares [1] - As of December 3, 2025, 加和国际控股's stock closed at HKD 0.12, reflecting a decrease of 3.97% with a trading volume of 280,000 shares and a transaction value of HKD 34,300 [1] Group 2 - 加和国际控股 has a market capitalization of HKD 103 million and ranks 28th in the medical device II industry [1] - There has been low attention from investment banks, with no ratings provided for the stock in the past 90 days [1]

Core Viewpoint - The chairman of MicroTech Medical (02235.HK), Zheng Pan, has reduced his stake by selling 2.09 million shares at a price of HKD 6.9 per share, totaling HKD 14.42 million, resulting in a new holding of approximately 38.70 million shares, representing 22.88% of the company [1][1][1]. Group 1: Shareholder Activity - Zheng Pan sold 2.09 million shares of MicroTech Medical at HKD 6.9 each, amounting to HKD 14.42 million [1][1][1]. - After the sale, his remaining shares are approximately 38.70 million, which is 22.88% of the total shares [1][1][1]. Group 2: Stock Performance - As of November 24, 2025, MicroTech Medical-B closed at HKD 6.8, unchanged from the previous trading day, with a trading volume of 79,500 shares and a turnover of HKD 532,700 [1][1][1]. - The stock has received a "Buy" rating from one investment bank in the last 90 days [1][1][1]. Group 3: Company Metrics - MicroTech Medical-B has a market capitalization of HKD 1.132 billion, ranking 21st in the medical device II industry [1][1][1]. - Key performance indicators include: - ROE: -1.36% (industry average: -4.03%, rank: 20) [1][1][1] - Market capitalization: HKD 1.132 billion (industry average: HKD 4.94 billion, rank: 21) [1][1][1] - Revenue: HKD 441 million (industry average: HKD 1.195 billion, rank: 18) [1][1][1] - Net profit margin: -0.93% (industry average: -16.5%, rank: 18) [1][1][1] - Gross profit margin: 51.66% (industry average: 54.89%, rank: 18) [1][1][1] - Debt ratio: 10.8% (industry average: 29.03%, rank: 5) [1][1][1].